TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07570979: An Open-label, Multi-center, First in Human Phase I Global Dose Escalation and Expansion Study of INR731 Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Can

Sponsor: Novartis Pharmaceuticals · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 208 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$4,492,488

Rescue Site Savings

+$2,953,104

Unlock Full NCT07570979 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07570979 Rescue Dossier →